Abstract
Objective: Technetium-99m (99mTc) bicisate is a radiopharmaceutical imaging agent useful for assessing regional cerebral perfusion. We will present the details of two procedures used to confirm the radiochemical purity (RCP) of 99mTc-bicisate.
Methods: After radiolabeling, the performance of a quality control procedure is recommended to confirm the RCP of 99mTc-bicisate. For routine quality control, a single thin-layer chromatographic (TLC) method is sufficient for determining the RCP of the kit. For research purposes, a second TLC method has been developed to provide quantification of individual radioimpurities.
Results: Information on the radiolabeling reaction and potential radioimpurities is provided to illustrate the factors that must be evaluated in the development of TLC procedures for this kit. Data are provided which demonstrate the specificity and ruggedness of each procedure.
Conclusion: Implementation of these two TLC procedures should assist the user in obtaining accurate RCP measurements.
